Atomoxetine, a selective norepinephrine transporter (NET) blocker, increases standing blood
pressure and improves neurogenic orthostatic hypotension (NOH)-related symptoms to a greater
extent than midodrine, the current standard of care. Atomoxetine could be a new therapeutic
alternative for the treatment of NOH in patients with autonomic failure, particularly those
with multiple system atrophy (MSA).
The proposed study consists of an open-label, dose-optimization phase followed by a
randomized, double-blind, placebo-controlled, 2x2 crossover phase.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health